Australia markets close in 4 hours 33 minutes

Imugene Limited (IMU.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.2820+0.0220 (+8.46%)
As of 11:16AM AEST. Market open.

Imugene Limited

37 Bligh Street
Sydney, NSW 2000

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 

Key executives

NameTitlePayExercisedYear born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExec. Chairman369.32kN/A1956
Ms. Leslie ChongCEO, MD & Exec. Director719.13kN/AN/A
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.Chief Technology Officer328.88kN/AN/A
Mr. Phillip Allen Hains BBus(Acc), CA, MBACFO & Joint Company Sec.N/AN/A1959
Dr. Anthony GoodSr. VP of Clinical ResearchN/AN/AN/A
Dr. Monil Shah M.B.A., Pharm.D.Chief Bus. OfficerN/AN/AN/A
Ms. Ursula McCurrySr. VP of Clinical OperationsN/AN/AN/A
Mr. Nathan Jong C.A.Joint Company Sec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Corporate governance

Imugene Limited’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.